Fig. 1: GRAIL expression is upregulated in the livers of patients with nonalcoholic fatty liver disease (NAFLD) and obese mice. | Cell Death & Disease

Fig. 1: GRAIL expression is upregulated in the livers of patients with nonalcoholic fatty liver disease (NAFLD) and obese mice.

From: E3 ubiquitin ligase Grail promotes hepatic steatosis through Sirt1 inhibition

Fig. 1

A, B Histological images of liver sections from NAFLD or normal patients stained using Grail antibody and hematoxylin and eosin stain (scale bar, 50 μm). C–E Grail protein and mRNA expression in the liver of mice subjected to high-fat diet (HFD) and in controls fed on normal chow diet (ND). F, G HepG2 (H, I), AML12 (J), murine primary hepatocytes (K), and THLE-2 cells were stimulated with palmitic acid (800 μM) for 24 h and GRAIL expression was examined by immunoblotting. The mRNA levels of GRAIL, fatty acid synthase (FASN), sterol regulatory element-binding protein 1c (SREBP-1c), and CD36 were measured by real-time quantitative polymerase chain reaction (RT-qPCR). The data are presented as mean ± standard deviation (SD). **P < 0.01; ***P < 0.001, Student’s t-test.

Back to article page